Paysign Inc Stock Price, News & Analysis

Paysign (NASDAQ: PAYS) reported record Q3 2025 results with $21.60M revenue, up 41.6% year-over-year, and net income of $2.22M (diluted EPS $0.04), up 54.2%. Adjusted EBITDA was $5.04M (23.3% margin), up 78.1%. Pharma patient affordability revenue grew 141.9% to $7.92M with 105 active programs at quarter end (118 at Oct 31). Plasma revenue rose 12.4% to $12.86M with 595 centers. Ended Q3 with $7.53M unrestricted cash and zero bank debt; unrestricted cash was reduced by timing on $9.36M passthrough claim items. Updated 2025 guidance: revenue $80.5M–$81.5M, net income $7.0M–$8.0M, Adjusted EBITDA $19M–$20M.

Paysign (NASDAQ: PAYS) will host its third quarter 2025 earnings call on Wednesday, November 12, 2025 at 5:00 p.m. ET. The company will discuss third-quarter results and answer questions from registered financial professionals.

Participant details: U.S. dial-in 877.407.2988; International +1.201.389.0923; Webcast available live. Replay: dial 877.660.6853 or +1.201.612.7415, Conference ID 13756404; replay available through May 12, 2026. To ask questions live, financial professionals must register by emailing ir@paysign.com by 5:00 p.m. ET on Friday, November 7, 2025.

Paysign (NASDAQ: PAYS), a provider of patient affordability programs and donor compensation solutions, has appointed Jose Garcia as Executive Vice President of Life Science Solutions. Garcia, with over 20 years of executive experience, will lead the market strategy for the company's engagement and management solutions in life sciences.

Prior to joining Paysign, Garcia served as Vice President of Client Relationships at QualTex Laboratories, where he strengthened partnerships in blood and plasma collection industries. He previously held VP of Sales positions at BioBridge Global companies, QualTex and GenCure, expanding their life sciences presence.

Paysign (NASDAQ: PAYS) announced a proposed settlement of multiple stockholder derivative actions related to alleged false and misleading statements made between March 2019 and September 2020. The settlement addresses claims that the company's leadership breached fiduciary duties by failing to maintain effective IT controls and internal financial reporting controls.

The settlement includes implementation of corporate governance reforms to be maintained for 5 years. Defendants' insurers will pay $607,500 in attorneys' fees and expenses, plus service awards of up to $2,000 for each of the four plaintiffs. The settlement hearing is scheduled for November 14, 2025.

The litigation involved allegations of insider trading by four executives totaling $5.7 million in proceeds and delayed financial filings. Current stockholders can object to the settlement by October 24, 2025.

Paysign (NASDAQ: PAYS) has announced the opening of a new 30,000 square foot patient service support center in Henderson, Nevada. The expansion increases the company's support capacity by 4x to meet growing demand in its patient affordability business.

The facility will enhance Paysign's ability to provide dedicated support specialists for individual programs and clients, leveraging its proprietary Dynamic Business Rules technology to optimize copay assistance programs. The company's patient affordability segment has shown remarkable growth, with revenues increasing 190% year-over-year in Q2 2025.

Paysign (NASDAQ: PAYS), a provider of payment solutions for life sciences industries, has announced its participation in the ninth annual Lake Street Best Ideas Growth BIG9 Conference on September 11, 2025. The invitation-only event facilitates interactions between small-cap companies and top institutional investors.

Chief Financial Officer Jeff Baker will represent Paysign at the conference, conducting one-on-one and group meetings with institutional investors throughout the event.

Paysign (NASDAQ: PAYS), a provider of patient affordability programs and payment solutions for life sciences industries, has appointed Dan Henry as Chairman of the Board. Henry succeeds Mark Newcomer, who will continue as President and CEO. Henry, who has served on Paysign's board since 2018, brings over 30 years of fintech leadership experience.

Henry's extensive background includes co-founding Euronet Worldwide, serving as CEO of NetSpend Corporation where he led its IPO and $1.4 billion acquisition by TSYS, and most recently serving as CEO of Green Dot Corporation. He currently chairs Paysign's Executive Compensation Committee and holds a B.S. in Business Administration from the University of Missouri.

Paysign (NASDAQ: PAYS), a provider of prepaid card programs and financial technology solutions, announced its participation in the upcoming Oppenheimer 28th Annual Technology, Internet & Communications Conference. The virtual conference will be held from August 11-13, 2025.

Chief Financial Officer Jeff Baker will represent the company with a presentation scheduled for Tuesday, August 12, at 10:45 a.m. EDT. The conference aims to showcase technological innovations and provide investors with insights into companies leading these advancements.

Paysign (NASDAQ: PAYS) reported strong Q2 2025 financial results with total revenues of $19.08 million, up 33.1% year-over-year. Net income reached $1.39 million, a 99.1% increase, with diluted EPS of $0.02. Adjusted EBITDA grew 101.8% to $4.51 million.

The company's pharma patient affordability segment showed exceptional growth with revenue increasing 189.9%, while adding 7 new programs for a total of 97 active programs. The plasma business added 123 new centers but saw a 4.7% revenue decline due to industry-wide plasma oversupply. The company exited Q2 with $11.8 million in unrestricted cash and zero debt.

Management raised full-year 2025 guidance, projecting revenues between $76.5-78.5 million, representing 32.7% growth at midpoint, with Adjusted EBITDA expected between $18.0-20.0 million.